Qube Research & Technologies (QRT)
ADMA icon

Qube Research & Technologies (QRT)’s ADMA Biologics ADMA Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11M Sell
1,316,568
-513,102
-28% -$4.68M 0.01% 1232
2026
Q1 		$16.5M Buy
+1,829,670
New +$28.9M 0.02% 985
2025
Q4 		– Sell
-164,125
Closed -$2.41M – 3640
2025
Q3 		$2.41M Sell
164,125
-125,060
-43% -$2.14M ﹤0.01% 2147
2025
Q2 		$5.27M Buy
289,185
+41,699
+17% +$850K 0.01% 1665
2025
Q1 		$4.91M Sell
247,486
-355,281
-59% -$6.14M 0.01% 1544
2024
Q4 		$10.3M Buy
602,767
+294,685
+96% +$5.54M 0.01% 1066
2024
Q3 		$6.16M Sell
308,082
-108,339
-26% -$1.68M 0.01% 1286
2024
Q2 		$4.66M Buy
416,421
+228,077
+121% +$1.91M 0.01% 1288
2024
Q1 		$1.24M Sell
188,344
-583,127
-76% -$3.19M ﹤0.01% 2023
2023
Q4 		$3.49M Sell
771,471
-433,177
-36% -$1.6M 0.01% 1234
2023
Q3 		$4.31M Buy
1,204,648
+224,696
+23% +$865K 0.01% 1001
2023
Q2 		$3.62M Buy
979,952
+444,455
+83% +$1.65M 0.01% 805
2023
Q1 		$1.77M Buy
535,497
+493,424
+1,173% +$1.71M 0.01% 1059
2022
Q4 		$163K Sell
42,073
-250,890
-86% -$774K ﹤0.01% 1875
2022
Q3 		$712K Buy
+292,963
New +$703K ﹤0.01% 1331
2022
Q2 		– Sell
-148,080
Closed -$271K – 2435
2022
Q1 		$271K Buy
148,080
+43,520
+42% +$67.9K ﹤0.01% 1839
2021
Q4 		$147K Buy
104,560
+92,773
+787% +$122K ﹤0.01% 2056
2021
Q3 		$13K Sell
11,787
-120,800
-91% -$169K ﹤0.01% 2013
2021
Q2 		$212K Buy
132,587
+96,397
+266% +$170K ﹤0.01% 1765
2021
Q1 		$64K Buy
+36,190
New +$82.8K ﹤0.01% 1772
2020
Q3 		– Sell
-35,569
Closed -$104K – 1623
2020
Q2 		$104K Buy
+35,569
New +$102K ﹤0.01% 1512

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Qube Research & Technologies (QRT)'s ADMA Position: Q2 2026 in Review

Qube Research & Technologies (QRT) reduced its ADMA Biologics (ADMA) stake by 28% in Q2 2026, selling an estimated $4.68M and leaving 1,316,568 shares worth $11M. The position accounts for 0.01% of the portfolio, ranked #1232.

Qube Research & Technologies (QRT) first reported a position in ADMA in Q2 2020 and has held it in 21 quarters since. The position peaked at $16.5M in Q1 2026. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Qube Research & Technologies (QRT) held 1,316,568 shares of ADMA Biologics worth $11M as of Q2 2026.
  • Qube Research & Technologies (QRT) sold 513,102 ADMA Biologics shares in Q2 2026, an estimated $4.68M.
  • ADMA Biologics made up 0.01% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #1232 holding.
  • Qube Research & Technologies (QRT) first reported a position in ADMA Biologics in Q2 2020 and has held it in 21 quarters since.
  • Qube Research & Technologies (QRT)'s ADMA Biologics position peaked at $16.5M in Q1 2026.
  • 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.